Oncological Outcomes of Adjuvant Radiotherapy for Partial Ureterectomy in Distal Ureteral Urothelial Carcinoma Patients

Hong-Zhen Li, Xiaoying Li, Xian-Shu Gao, Xin Qi, Ming-Wei Ma, Shangbin Qin, Hong-Zhen Li, Xiaoying Li, Xian-Shu Gao, Xin Qi, Ming-Wei Ma, Shangbin Qin

Abstract

Purpose: We retrospectively analyzed the oncological outcomes of T3 or G3 distal ureteral urothelial carcinoma (DUUC) underwent partial ureterectomy (PU) followed by adjuvant radiotherapy (ART).

Methods: From January 2008 to September 2019, clinical data from a total of 221 patients with pathologic T3 or G3 who underwent PU or RNU at our hospital were analyzed. 17 patients of them were treated with PU+ART, 72 with PU alone and 132 with radical nephroureterectomy (RNU). Clinicopathologic outcomes were evaluated. Survival was assessed using the Kaplan-Meier method. Cox regression addressed recurrence-free survival (RFS), metastasis-free survival (MFS), cancer specific survival (CSS) and overall survival (OS).

Results: Median age and follow-up time were 68 (IQR 62-76) years old and 43 (IQR 28-67) months, respectively. In univariate and multivariable analyses, no lymph node metastasis(LNM) and ART were independent prognostic factors of RFS (p=0.031 and 0.016, respectively). ART significantly improved 5-year RFS compared with the PU alone, (67.6% vs. 39.5%, HR: 2.431, 95%CI 1.210-4.883, p=0.039). There was no statistical difference in 5-year RFS between PU+ART and RNU groups (67.6% vs. 64.4%, HR=1.113, 95%CI 0.457-2.712, p=0.821). Compared with PU alone or RNU, PU+ART demonstrated no statistical difference in 5-year MFS (PU+ART 73.2%, PU 57.2%, RNU69.4%), CSS (70.7%, 55.1%, 76.6%, respectively), and OS (70.7%, 54.1%, 69.2%, respectively).

Conclusions: For distal ureteral urothelial carcinoma patients with T3 or G3, adjuvant radiotherapy could significantly improve recurrence-free survival compared with partial ureterectomy alone. There was no significant difference between survival outcomes of PU+ART and radical nephroureterectomy.

Keywords: adjuvant radiotherapy; partial ureterectomy; radical nephroureterectomy; recurrence-free survival (RFS); urothelial carcinoma.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Li, Gao, Qi, Ma and Qin.

Figures

Figure 1
Figure 1
Kaplan–Meier curves for: RFS (A), MFS (B), CSS (C), OS (D) after PU+RT (blue line), PU alone (green line) or RNU (black line).

References

    1. Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. . European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol (2020) 79(1):62–79. doi: 10.1016/j.eururo.2020.05.042
    1. Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, et al. . Oncologic Outcomes of Kidney-Sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol (2016) 70(6):1052–68. doi: 10.1016/j.eururo.2016.07.014
    1. Cutress ML, Stewart GD, Tudor EC, Egong EA, Wells-Cole S, Phipps S, et al. . Endoscopic Versus Laparoscopic Management of Noninvasive Upper Tract Urothelial Carcinoma: 20-Year Single Center Experience. J Urol (2013) 189(6):2054–60. doi: 10.1016/j.juro.2012.12.006
    1. Raymundo EM, Lipkin ME, Banez LB, Mancini JG, Zilberman DE, Preminger GM, et al. . Third Prize: The Role of Endoscopic Nephron-Sparing Surgery in the Management of Upper Tract Urothelial Carcinoma. J Endourol (2011) 25(3):377–84. doi: 10.1089/end.2010.0276
    1. Jwa E, Kim YS, Ahn H, Kim CS, Lee JL, Kim SO, et al. . Adjuvant Radiotherapy for Stage III/IV Urothelial Carcinoma of the Upper Tract. Anticancer Res (2014) 34(1):333–8. doi: 10.1016/j.lungcan.2013.10.009
    1. Chen B, Zeng ZC, Wang GM, Zhang L, Lin ZM, Sun LA, et al. . Radiotherapy may Improve Overall Survival of Patients With T3/T4 Transitional Cell Carcinoma of the Renal Pelvis or Ureter and Delay Bladder Tumour Relapse. BMC Cancer (2011) 11:297. doi: 10.1186/1471-2407-11-297
    1. Jang NY, Kim IA, Byun SS, Lee SE, Kim JS. Patterns of Failure and Prognostic Factors for Locoregional Recurrence After Radical Surgery in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Adjuvant Radiotherapy. Urol Int (2013) 90(2):202–6. doi: 10.1159/000343729
    1. Li X, Cui M, Gu X, Fang D, Li H, Qin S, et al. . Pattern and Risk Factors of Local Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma. World J Surg Oncol (2020) 18(1):114. doi: 10.1186/s12957-020-01877-w
    1. Speakman MJ, Khastgir L. Campbell-Walsh Urology 9th Edition, e-edition. BJU Inter (2007) 100(2):453–4. doi: 10.1111/j.1464-410x.2007.07073.x
    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin (2020) 70(1):7–30. doi: 10.3322/caac.21590
    1. Bagrodia A, Kuehhas FE, Gayed BA, Wood CG, Raman JD, Kapur P, et al. . Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. Urology (2013) 81(5):972–7. doi: 10.1016/j.urology.2012.12.059
    1. Colin P, Ouzzane A, Pignot G, Ravier E, Crouzet S, Ariane MM, et al. . Comparison of Oncological Outcomes After Segmental Ureterectomy or Radical Nephroureterectomy in Urothelial Carcinomas of the Upper Urinary Tract: Results From a Large French Multicentre Study. BJU Int (2012) 110(8):1134–41. doi: 10.1111/j.1464-410X.2012.10960.x

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir